Shares of Arcus Biosciences, Inc. (NYSE:RCUS - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $21.1429.
Several research firms recently commented on RCUS. Wedbush reiterated an "outperform" rating and issued a $33.00 price target on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Wells Fargo & Company reduced their price target on shares of Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating for the company in a research report on Thursday, August 7th. Morgan Stanley reduced their price target on shares of Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group reduced their price target on shares of Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Arcus Biosciences from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th.
Read Our Latest Analysis on Arcus Biosciences
Arcus Biosciences Trading Up 1.5%
Shares of RCUS traded up $0.15 during trading on Tuesday, reaching $10.06. 81,160 shares of the company traded hands, compared to its average volume of 1,028,764. Arcus Biosciences has a twelve month low of $6.50 and a twelve month high of $18.98. The stock has a market cap of $1.07 billion, a PE ratio of -3.16 and a beta of 0.89. The stock has a 50-day simple moving average of $9.16 and a 200-day simple moving average of $9.37. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18.
Arcus Biosciences (NYSE:RCUS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.03. The firm had revenue of $160.00 million during the quarter, compared to analysts' expectations of $32.86 million. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The business's quarterly revenue was up 310.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.02) earnings per share. On average, analysts anticipate that Arcus Biosciences will post -3.15 earnings per share for the current year.
Institutional Trading of Arcus Biosciences
A number of hedge funds have recently made changes to their positions in RCUS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Arcus Biosciences by 2.5% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company's stock valued at $506,000 after purchasing an additional 833 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Arcus Biosciences by 8.0% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,398 shares of the company's stock worth $142,000 after acquiring an additional 1,294 shares during the period. Parallel Advisors LLC grew its holdings in Arcus Biosciences by 1.6% during the second quarter. Parallel Advisors LLC now owns 88,007 shares of the company's stock worth $716,000 after acquiring an additional 1,422 shares during the period. Ameritas Investment Partners Inc. grew its holdings in Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company's stock worth $57,000 after acquiring an additional 1,796 shares during the period. Finally, Maryland State Retirement & Pension System grew its holdings in Arcus Biosciences by 10.9% during the first quarter. Maryland State Retirement & Pension System now owns 20,202 shares of the company's stock worth $159,000 after acquiring an additional 1,986 shares during the period. Institutional investors and hedge funds own 92.89% of the company's stock.
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
See Also

Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.